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 Abstract 
 Objectives. To evaluate the eﬃ  cacy and safety of rituximab in Japanese patients with systemic 
lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immuno-
suppressive therapy. 
 Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and 183, 
and were followed for 53 weeks after the ﬁ rst dose of rituximab. Overall disease activity was 
assessed monthly using a British Isles Lupus Assessment Group activity index. Patients with LN 
(Upr/Ucr    1.0 at study entry) were identiﬁ ed and their renal responses were evaluated according 
to the criteria proposed by the American College of Rheumatology (ACR) and the Lupus Nephritis 
Assessment with Rituximab (LUNAR) study. 
 Results. A total of 34 patients were enrolled and received at least one dose of rituximab. Decrease 
in disease activity was achieved in 16 (76.5%) out of 34 patients. In 17 patients with LN, response 
rates of 58.8% and 52.9% by ACR and LUNAR criteria, respectively, were seen. Successful steroid 
tapering was achieved in association with disease remission. Rituximab was well tolerated, and 
most adverse drug reactions were grade 1 – 2 in severity. 
 Conclusions. Rituximab is eﬀ ective for treatment of Japanese patients with SLE and LN refractory 
to conventional therapy. 
http://informahealthcare.com/mor
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either as monotherapy or in combination with immunosuppressive 
medications, was safe and eﬀ ective for the treatment of SLE and 
LN [4 – 8]. In contrast, two large-scale, double-blind, placebo-
controlled phase III clinical studies to examine the eﬃ  cacy and 
safety of rituximab in patients with active SLE (Exploratory Phase 
II/III SLE Evaluation of Rituximab [EXPLORER]) [9] or SLE 
with active proliferative LN (Lupus Nephritis Assessment with 
Rituximab [LUNAR]) [10] did not demonstrate superiority of ritux-
imab over placebo. However, a greater number of subjects in the 
rituximab arms of the EXPLORER and LUNAR studies achieved 
remission and showed serologic improvement in serum complement 
C3 and C4 levels, and reduced anti-double-stranded DNA (dsDNA) 
antibody levels than did those receiving placebo [10,11]. 
 To date, rituximab has not been approved for the treatment of 
LN by the US Food and Drug Administration or the European 
Medicines Agency; nevertheless, the American College of Rheu-
matology (ACR) [12] and European League Against Rheumatism 
and European Renal Association-European Dialysis and Trans-
plant Association (EULAR/ERA-EDTA) guidelines [13] recom-
mend rituximab for the treatment of patients with LN who are 
refractory to conventional immunosuppressive therapy including 
cyclophosphamide (CYC) and mycophenolate mofetil (MMF). 
 
© 2015 Japan College of Rheumatology. Published by Taylor & Francis.
 DOI: 10.3109/14397595.2015.1060665
 History 
Received  27  February  2015 
Accepted  5  June  2015 
Published online  18  August  2015 
 Introduction 
 Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease with variable manifestations. Lupus nephritis (LN) is one 
of the most serious complications of SLE and develops in 50 – 60% 
of SLE patients within the ﬁ rst 10 years of disease onset [1]. LN is 
one of the main causes of morbidity and mortality in SLE patients 
and signiﬁ cantly reduces life expectancy to 88% at 10 years [2]. 
Current treatments for SLE include immunosuppressive drugs 
such as corticosteroids and cytostatics; however, the disease may 
become refractory to conventional treatments over time. Long-term 
life expectancy and renal survival of SLE patients with LN have 
progressively increased with the introduction of newer treatments, 
earlier referral, and improved diagnostic criteria [3]. 
 A number of observational, open-label trials revealed that B-cell 
depletion therapy with rituximab, a chimeric anti-CD20 antibody, 
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 To examine the safety and eﬃ  cacy of rituximab in Japanese 
SLE patients, we have conducted a multicenter, open-label, phase 
II clinical trial of rituximab in patients with SLE refractory to con-
ventional immunosuppressive therapy. To evaluate the applicability 
of the ACR and EULAR/ERA-EDTA guidelines to Japanese SLE 
patients with LN, a post-hoc analysis of the safety and eﬃ  cacy of 
rituximab was done in a subset of LN patients from the study. 
 Materials and methods 
 Study design and patients 
 An open-label, multicenter, phase II study of rituximab in Japanese 
patients with refractory SLE was conducted between July 2007 and 
May 2010 in seven centers across Japan. The study was performed 
in accordance with the principles of the Declaration of Helsinki 
and Japanese GCP requirements for conducting clinical trials. The 
study was approved by the local ethics committees of all seven par-
ticipating institutions and was registered in the University Hospital 
Medical Information Network database (UMIN000000763). 
 Patients underwent an initial screening visit and eligible patients 
were enrolled after giving informed consent. Inclusion criteria 
included age, 16 – 75 years; a history of meeting the 1997 ACR 
criteria for SLE [14] with positive antinuclear antibodies (ANAs); 
and active disease in any organ system at screening despite at least 
2 weeks of treatment with prednisolone    0.75 mg/kg/day. Patients 
were excluded if they had a history of cancer or serious recurrent or 
chronic infection; uncontrolled medical disease; previous treatment 
with B-cell-targeted therapy; aspartate aminotransferase or alanine 
aminotransferase levels    2.5-fold of the upper limit of normal 
(ULN); amylase or lipase level    2-fold of the ULN; neutrophil 
counts    1.0    10 3  μ L; positive results of hepatitis B or hepatitis C 
serology; hemoglobin concentration    7 gm/dL (unless caused by 
hemolytic anemia due to SLE); platelet counts    10,000/ μ L; and 
serum creatinine levels    2.5 mg/dL. 
 Treatment 
 Patients continued to receive corticosteroid and any concomitant 
immunosuppressants at the same dose used before study entry. 
For those with high disease activity at screening, a dose increase 
in corticosteroid was allowed at the investigator ’ s discretion, and 
should have started at least 7 days before initiation of rituximab 
treatment. Rituximab was administered at a dose of 1,000 mg 
given 2 weeks apart (days 1 and 15), which was repeated after 
6 months from the ﬁ rst rituximab administration (days 169 and 
183), similar to the EXPLORER and LUNAR studies (a total of 
four doses). To reduce or avoid infusion-related reactions associ-
ated with rituximab administration, acetaminophen (400 mg, po), 
chlorpheniramine maleate (2 mg, po), and methylprednisolone 
(100 mg, iv) were administered before each rituximab infusion. 
Once clinical improvement was observed, the dose of corticos-
teroid was tapered by 20% every 2 – 4 weeks and not allowed to 
re-increase once tapered. 
 Assessments and endpoints 
 Patients were followed for 53 weeks after the ﬁ rst rituximab 
administration on a monthly basis. Systemic disease activity was 
evaluated by the British Isles Lupus Assessment Group (BILAG) 
activity index [15]. Periodic laboratory testing of the levels of cir-
culating B cells; complements C3, C4, and CH50; and anti-dsDNA 
antibodies was also performed. 
 Overall disease activity was assessed in accordance with the 
approach reported by Dr. Isenberg of University College of Lon-
don [6]. Disease remission was deﬁ ned as  “ a change from BILAG 
A or B score to a BILAG C or D score in every organ system. ” 
Partial remission was deﬁ ned as  “ a change from a BILAG A or 
B score to a C or D score in at least one organ system, but with 
presence of one BILAG A or B score in another organ system. ” No 
improvement was deﬁ ned as  “ a BILAG A or B score that remained 
unchanged at week 53. ” For patients with involvement of only one 
organ, remission was a change from a BILAG A or B score to C 
or D score, and partial remission was a change from a BILAG A 
score to B score. 
 Renal responses were graded as complete renal response 
(CRR), partial renal response (PRR), or no response (NR) based 
on the criteria used in the LUNAR study [10] and ACR guidelines 
[16]. The overall renal response rate (ORR) was deﬁ ned as  “ the 
sum of the CRR and PRR. ” Based on the LUNAR study, CRR 
was deﬁ ned as  “ normal serum creatinine levels ” if abnormal at 
baseline, or serum creatinine levels    115% of baseline if normal 
at baseline; inactive urinary sediment (   5 red blood cells (RBCs)/
high-power ﬁ eld (hpf) and absence of RBC casts); and urinary pro-
tein to urinary creatinine (Upr/Ucr) ratio    0.5. PRR was deﬁ ned 
as  “ serum creatinine levels    115% of baseline; RBCs/hpf    50% 
above baseline with no RBC casts; and    50% decrease in Upr/
Ucr ratio to    1.0 (if baseline Upr/Ucr ratio    3.0) or to    3.0 (if 
baseline Upr/Ucr ratio    3.0). ” Based on the ACR guidelines, 
CRR was deﬁ ned as  “ a    25% increase in estimated glomerular 
ﬁ ltration rate (eGFR) if baseline values were abnormal; inactive 
urinary sediment (   5 RBCs/hpf and absence of RBC casts); and 
at least a 50% decrease in Upr/Ucr ratio to 0.2. ” PRR was deﬁ ned 
as  “ stable eGFR (at least 75% of baseline value); inactive urinary 
sediment; and at least a 50% decrease in Upr/Ucr ratio to 0.2 – 2.0. ” 
Patients were classiﬁ ed as NR if CRR or PRR criteria were not 
met. Patients who received any additional therapies for disease 
control, including dose increase of steroid and/or immunosuppres-
sants, were also classiﬁ ed as NR. 
 An adverse event (AE) was deﬁ ned as  “ any untoward medical 
occurrence (e.g., sign, symptom, disease, syndrome, concurrent 
illness, or clinically signiﬁ cant abnormal laboratory ﬁ nding) that 
newly emerged or worsened during the study period relative to 
pretreatment baseline, regardless of the suspected cause. ” AEs 
were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) Version 3.0. 
Adverse drug reactions (ADRs) were deﬁ ned as  “ any AEs for 
which an association with rituximab could not be completely ruled 
out. ” Infusion reactions were deﬁ ned as  “ any ADRs occurring dur-
ing or within 24 h following the completion of rituximab infusion. ” 
Serious ADRs were deﬁ ned as  “ those that resulted in death, were 
life threatening, or required prolonged inpatient hospitalization. ” 
 Statistical analyses 
 The diﬀ erences in median values of BILAG activity score, SLE 
biomarkers (i.e., C3, C4, CH50, anti-DNA antibodies, urinalysis, 
and eGFR), and steroid doses at screening and at week 53 were 
examined by Wilcoxon ’ s matched pairs signed-rank test to deter-
mine statistical signiﬁ cance. All statistical analyses were carried 
out using SAS software (Cary, NC, USA). Patients with Upr/Ucr 
ratio    1.0 at screening were included in the post-hoc analysis and 
percentages and 95% conﬁ dence intervals of subjects who met the 
response criteria were calculated. For those who dropped out of 
the study before week 53 for any reason, clinical data obtained at 
the last observation were used for analyses applying the last obser-
vation carried forward approach. 
 Results 
 Patient characteristics 
 A total of 34 patients were enrolled in this phase II study. 
Baseline demographic and clinical characteristics are summarized 
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in Table 1. Of the 34 patients enrolled in the phase II study, 17 
had renal involvement with Upr/Ucr    1.0 at screening and were 
included in the post-hoc analysis; of these, 10 had class III/IV LN 
based on the International Society of Nephrology or ISN/Renal 
Pathology Society or RPS classiﬁ cation [17], one had class IIb LN, 
one had class VI LN, and ﬁ ve had never undergone a histopatho-
logical examination. Eight patients dropped out of the study pre-
maturely before week 53: two patients for SLE ﬂ are, two were lost 
to follow-up, and one patient each for use of prohibited medication 
for treatment of concurrent illness other than SLE, withdrawal of 
informed consent, an AE not related to rituximab, and an ADR 
related to rituximab. Of the two patients who dropped out because 
of SLE ﬂ are, one was a 30-year-old female patient with highly 
active class IV LN who presented with massive proteinuria (Upr/
Ucr    10.0) and hematuria (   50 RBCs/hpf) at study entry. She 
had LN for 7 months and was previously treated with steroid pulse, 
plasma exchange, and hemodialysis. High disease activity persisted 
even after the fourth dose of rituximab, and she was removed from 
the study to receive another intentional therapy. The other patient 
was a 22-year-old female patient with newly diagnosed class III 
LN. She presented at study entry with remarkably high levels of 
serum autoantibodies: ANA    1,280 IU/mL, anti-dsDNA    24 U/
mL, anti-Sm    500 U/mL, anti-RNP    500 U/mL, and anti-SS-A/
Ro    18.7 U/mL. She was removed from the study after two doses 
 Table 1. Baseline characteristics of the enrolled patients ( n    34). 
No. Previous therapy (other than PSL) Clinical manifestation
Initial PSL 
[mg/day]
Concomitant 
therapy
1  ― Nephritis (class IV) 55  ― 
2 IVCY, CYA, MZR Myelitis, neuropathy 40  ― 
3 IVCY Pyrexia, weight loss, lymphadenopathy, fatigue, anorexia, arthritis 
and arthralgia, dyspnea, cardiac failure, friction rub, lung ﬁ elds
50  ― 
4 IVCY, CYA, AZA Nephritis (class IV) 40 CYA
5 CYA, AZA, TAC Thrombocytopenia 10  ― 
6 IVCY, AZA Nephritis (class IV) 40 AZA
7 CYC, MZR, CYA, AZA, TAC Pyrexia, fatigue, arthralgia, dyspnea, Raynaud ’ s phenomenon, 
lymphocytopenia
35 CYA
8 CYA, AZA, MZR Pyrexia, nephritis (class III/IV) 15 CYA
9  ― Arthritis, nephritis (class IV) 60  ― 
10  ― Nephritis (class unknown) 60  ― 
11 IVCY, MTX Pyrexia, fatigue, anorexia, eﬀ usion, lung ﬁ elds, nephritis (class 
unknown)
90  ― 
12  ― Pyrexia, fatigue, mucosal ulcers, malar erythema, arthritis and 
arthralgia, nephritis (class IV)
55  ― 
13 IVCY, AZA, TAC, MTX, MMF Nephritis (class VI), anemia 35 MMF
14  ― Nephritis (class IV) 80  ― 
15 TAC, CYA Fatigue, anorexia, malar erythema, nephritis (class IIb) 30 CYA
16  ― Pyrexia, malar erythema, headache (unremitting) 45  ― 
17 IVCY Pyrexia, fatigue, nephritis, anemia, accelerated hypertension 60  ― 
18 IVCY, CYA Nephritis (class IV) 60  ― 
19  ― Weight loss, fatigue, malar erythema 55  ― 
20 IVCY, MZR, CYA, AZA, TAC, MMF Nephritis (class IV), anemia 30 MMF
21  ― Mononeuritis simplex, nephritis 50  ― 
22 CYA Thrombocytopenia 30 CYA
23 IVCY Maculopapular eruption-severe, perniotic skin lesions, and 
periungual erythema
50  ― 
24  ― Fatigue, anorexia, active discoid, confusion, nephritis, anemia, 
renal (urinary sediment)
40  ― 
25 CYC Malar erythema, headache 40  ― 
26  ― Malar erythema, headache (unremitting), anemia 50  ― 
27 IVCY Mononeuritis multiplex, neuropathy 35  ― 
28  ― Nephritis (class unknown) 45  ― 
29  ― Pyrexia, weight loss, fatigue, anorexia,  nephritis (IIIa), anemia 50  ― 
30  ― Fatigue, anorexia, anemia 40  ― 
31 IVCY Seizure, confusion 85  ― 
32  ― Maculopapular eruption, nephritis 35  ― 
33 IVCY, MZR, CYA Malar erythema, nephritis (class unknown) 55  ― 
34  ― Lymphadenopathy and fatigue (B) 35  ― 
 IVCY Intravenous cyclophosphamide,  CYA Cyclosporin A,  AZA Azathioprine,  TAC Tacrolimus,  MTX Methotrexate,  MMF Mycophenolate mofetil. 
of rituximab as per the investigator ’ s judgment to receive plasma 
exchange. 
 Clinical effi  cacy 
 Peripheral B cells were depleted rapidly after the ﬁ rst course of 
rituximab treatment in all 34 patients (Figure 1a and b). Overall 
disease activity as measured by the BILAG index improved after 
rituximab treatment. A total of 26 of 34 patients (76.5%) responded 
to rituximab therapy at week 53; of these, 16 (47.1%) achieved 
remission and 10 (29.4%) achieved partial remission. BILAG 
global score in 34 patients decreased signiﬁ cantly from a median 
of 12.5 (interquartile range [IQR]: 10.0 – 14.0) at baseline to 3.5 
(IQR: 1.0 – 6.0) at week 53 ( P    0.0001) (Figure 2). A signiﬁ cant 
dose reduction in concomitant prednisolone was achieved, from 
45.0 mg/day (IQR: 35.0 – 55.0) at baseline to 6.0 mg/day (IQR: 
5.0 – 8.9) at week 53 ( P    0.0001) (Figure 3). Serologic improve-
ments were also observed, with a signiﬁ cant increase in C3 levels 
(69.0 mg/dL [IQR: 48.8 – 82.0] at baseline vs. 88.5 mg/dL [IQR: 
81.5 – 103.8] at week 53;  P    0.0001; Figure 4); C4 (16.5 mg/dL 
[IQR: 8.0 – 322.0] at baseline vs. 22.0 mg/dL [IQR: 18.0 – 28.0] 
at week 53;  P    0.0001, data not shown); CH50 (31.2/mL [IQR 
14.7 – 39.4] at baseline vs. 39.0/mL [IQR: 34.0 – 46.7] at week 53; 
 P    0.0027, data not shown); and anti-dsDNA antibody levels 
Y. Tanaka et al. Mod Rheumatol, 2016; 26(1):80–8682 
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 Figure 1. B-cell response to rituximab. (a) CD19    cells. (b) CD20    cells. 
Patients received rituximab at a dose of 1,000 mg for a total of four doses 
at weeks 1, 3, 25, and 27. 
 Figure 2. Changes in BILAG global score from baseline to week 53. 
 Figure 3. Changes in concomitant PSL dose from baseline to week 53. 
 Figure 4. Changes in C3 levels from baseline to week 53. 
(20.5 IU/mL [IQR: 10.0 – 67.8] at baseline vs. 10.0 IU/mL [IQR: 
10.0 – 12.8] at week 53;  P    0.0001; Figure 5). In 17 patients with 
renal involvement, the median value of Upr/Ucr decreased from 
2.2 (IQR: 1.4 – 3.8) at baseline to 0.4 (IQR: 0.10 – 2.44) at week 53 
( P    0.0068; Figure 6). eGFR remained stable, with a median 
value of 71.3 mL/min/1.73 m 2 (IQR: 41.2 – 101.5) at baseline versus 
72.3 mL/min/1.73 m 2 (IQR: 56.8 – 93.0) at week 53 ( P    0.1928; 
Figure 7). The renal response rates in accordance with LUNAR 
and ACR criteria for all 17 patients with LN and for the 10 patients 
with histologically conﬁ rmed class III/IV LN are presented in 
Table 2. Response rate was higher in the 10 patients with class III/
IV LN than in all 17 LN patients. While the exact reason for this 
is not clear, patients with class III/IV LN had shorter disease dura-
tion (median: 16 months vs. 53 months), although the diﬀ erence 
was not signiﬁ cant because of the small sample size. Only one 
patient had class VI LN, which is deﬁ ned as advanced-stage LN 
with    90% of glomeruli globally sclerosed without residual activ-
ity. Patients with class VI LN are not expected to respond to drug 
therapies. Therefore, we speculate that the class III/IV LN popula-
tion enrolled in the study could have had reversible lesions that 
contributed to their apparent response rate. No pre-study patient 
characteristics were found to be associated with response in this 
study, because of the small sample size. 
 Safety 
 A total of 154 ADRs with a suspected relationship to rituximab 
were observed. Most of the ADRs were mild to moderate with 
grade 1 or 2 severity, and only ten were grade 3 or 4 (Table 3). 
One patient who developed grade 3 cerebral infarction had pre-
sented at study entry with neuropsychiatric lupus with continuous 
disabling headache. This patient dropped out of the study as per 
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 Figure 5. Changes in anti-ds DNA IgG from baseline to week 53. 
 Figure 6. Changes in Upr/Ucr from baseline to week 53. 
 Figure 7. Changes in eGFR from baseline to week 53. 
 Table 2. Renal response to rituximab treatment. 
CRR PRR ORR (95% CI)
ORR in 17 patients 
with LN
ACR criteria (%) 35.3 23.5 58.8 (32.9 – 81.6)
LUNAR criteria (%) 29.4 23.5 52.9 (27.8 – 77.0)
ORR in 10 patients 
with class III/
IV LN
ACR criteria (%) 40.0 30.0 70.0 (34.8 – 93.3)
LUNAR criteria (%) 40.0 20.0 60.0 (26.2 – 87.8)
 ACR American College of Rheumatology,  CI conﬁ dence interval,  CRR 
complete renal response,  LN lupus nephritis,  LUNAR Lupus Nephritis 
Assessment with Rituximab study,  ORR overall renal response,  PRR 
partial renal response. 
the investigator ’ s judgment. Grade ¾ cholecystitis, endometritis, 
and hypoferric anemia were observed in one patient who had pre-
sented at study entry with concurrent cholelithiasis, endometrial 
hyperplasia, and moderate hypoferric anemia. In both cases, the 
AEs were considered to most likely be associated with the underly-
ing diseases or concomitant illnesses; however, the relationship to 
rituximab was not completely ruled out by the treating investiga-
tors. All of the ADRs were reversible and resolved by supportive 
treatments. There were 14 infusion-related ADRs, all of which 
were mild to moderate with grade 1 or 2 severity (Table 4). All 
of the symptoms cleared spontaneously and none required treat-
ment discontinuation. None of the patients who participated in this 
study died. 
 Discussion 
 The outcome of this Japanese study demonstrates that rituximab is 
eﬀ ective for disease control and enables a reduction of corticoster-
oid dose in a cohort of Japanese SLE patients including a subset 
with LN who were refractory to conventional immunosuppressive 
therapy. Rituximab was also well tolerated, and all ADRs observed 
were previously known and mild to moderate in severity. The eﬃ  -
cacy of rituximab in the current study is consistent with the ﬁ nd-
ings from a retrospective analysis at University College London 
Hospital, in which 89% of patients with SLE (N    50) achieved 
remission or partial remission with rituximab [6]. A prospective 
registry study in France showed a 77% ORR with rituximab in 
113 evaluable SLE patients [18]. In another prospective registry of 
rituximab use in Europe, a 67% ORR was achieved in 164 patients 
with biopsy-proven LN [19]. It is interesting that these registry 
studies were intended to evaluate the usefulness of rituximab oﬀ -
label use in actual practice settings, and found favorable responses 
and acceptable tolerability for treatment of SLE and LN. A recent 
systematic analysis of 26 studies of rituximab in 300 patients with 
LN revealed eﬀ ective remission, with a 74% ORR in patients not 
suﬃ  ciently controlled with standard treatment [20]. Two other sys-
tematic reviews of oﬀ -label use of rituximab in SLE also suggested 
 Table 3. Grade 3/4 ADRs. 
Events No. of events
(Grade 4)
  Leukocytopenia 2
  Hypoferric anemia 1
(Grade 3)
  Bacterial enteritis 1
  Herpes zoster 1
  Endometritis 1
  Cholecystitis 1
  Cerebral infarction 1
  Anemia 2
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 Table 4. Infusion reactions. 
Number of events
Event Grade 1 Grade 2
Nausea 2 1
Arthralgia 1 1
Pyrexia 0 2
Headache 2 0
Abdominal pain 1 0
Tremulousness 1 0
Skin rash 0 1
Nasopharyngitis 1 0
Sinusitis 0 1
the usefulness of rituximab, not only for LN but also for other 
clinical manifestations of SLE [21,22]. Taken together, rituximab 
is worth considering as a therapeutic option for treatment of Japa-
nese patients with SLE and LN refractory to conventional therapy. 
Further, we showed that the treatment guidelines from ACR and 
EULAR/ERA-EDTA are also applicable to Japanese patients. 
 Previous randomized, double-blind, placebo-controlled trials of 
rituximab in patients with moderate and severe extra-renal SLE 
(EXPLORER) [9] or with class III or IV LN (LUNAR) [10] failed 
to show statistically signiﬁ cant improvements with rituximab over 
placebo. These randomized controlled trials addressed the hypoth-
esis that the addition of rituximab to the standard of care was supe-
rior to standard of care alone in controlling SLE activity. Several 
reasons have been considered to explain the failure of these trials; 
the aggressive background immunosuppressive therapy, including 
high-dose corticosteroids and full-dose MMF, may have masked 
any signiﬁ cant clinical beneﬁ t of rituximab [23]. It is noteworthy 
that, despite the results of these studies, much attention is still paid 
to rituximab as an option for treatment of SLE [24,25]. 
 In our study, signiﬁ cant dose reduction of concomitant steroid 
was achieved with rituximab treatment. It is interesting to note that 
this steroid-tapering eﬀ ect of rituximab has been reported previ-
ously, not only in LN [26,27] but also in other diseases such as anti-
neutrophil cytoplasmic antibody or ANCA-associated vasculitis 
[28], pemphigus [29], and steroid-dependent nephrotic syndrome 
[30,31]. Long-term steroid use is associated with clinically sig-
niﬁ cant systematic AEs, and therefore steroid-avoiding treatment 
protocols consisting of rituximab and MMF have been studied in 
LN in an investigator-initiated clinical study (Rituxilup). Prelimi-
nary results seem promising [32], and a prospective, international, 
multicenter, randomized controlled study is now underway [33]. 
Another investigator-initiated, international, multicenter study 
named RING: Rituximab for Lupus Nephritis with Remission as 
a Goal, in which rituximab therapy is repeated every 6 months for 
a total of four courses, is also ongoing [34]. Further studies are 
needed to clarify the optimal use of rituximab for the treatment 
of LN, and it is highly expected that the international cooperative 
studies of rituximab, which have been carefully designed based 
on the lessons learned from previous studies, may give us new 
insights into rituximab use for treatment of LN. 
 Acknowledgments 
 This study was sponsored by Zenyaku Kogyo Co., Ltd. We acknowledge 
the medical writing support of Dr. Stacey Tobin and Dr. J. Ludovic Crox-
ford of Edanz Group Ltd. 
 Conﬂ ict of interest 
 K. Endo and N. Mashino are employees of Zenyaku Kogyo Co., Ltd. Y. 
Tanaka has received consulting fees, speaking fees, and/or honoraria from 
Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-
Myers, Astellas, Eisai, Janssen, Pﬁ zer, Asahi-kasei, Eli Lilly, GlaxoSmith-
Kline, UCB, Teijin, MSD, and Santen, and has received research grants 
from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, 
Kyowa-Kirin, Abbvie, and Bristol-Myers. The other authors have no con-
ﬂ icts of interest to declare. 
 References 
 Dooley  MA ,  Aranow  C ,  Ginzler  EM .  Review of ACR renal criteria in 1. 
systemic lupus erythematosus .  Lupus  2004 ;  13(11) : 857 – 60 . 
 Cervera  R ,  Khamashta  MA ,  Font  J ,  Sebastiani  GD ,  Gil  A , 2. 
Lavilla  P ,  et  al ; European Working Party on Systemic Lupus 
Erythematosus . Morbidity and mortality in systemic lupus 
erythematosus during a 10-year period: a comparison of early and late 
manifestations in a cohort of 1,000 patients .  Medicine (Baltimore) . 
 2003 ; 82(5) : 299 – 308 . 
 Moroni  G ,  Quaglini  S ,  Gallelli  B ,  Banﬁ   G ,  Messa  P ,  Ponticelli  C . 3. 
 Progressive improvement of patient and renal survival and reduction 
of morbidity over time in patients with lupus nephritis (LN) followed 
for 20 years .  Lupus.  2013 ; 22(8) : 810 – 8 . 
 Tanaka  Y ,  Yamamoto  K ,  Takeuchi  T ,  Nishimoto  N ,  Miyasaka  N , 4. 
 Sumida  T ,  et  al .  A multicenter phase I/II trial of rituximab for refractory 
systemic lupus erythematosus .  Mod Rheumatol.  2007 ; 17(3) : 191 – 7 . 
 Leandro  MJ ,  Edwards  JC ,  Cambridge  G ,  Ehrenstein  MR , 5. 
Isenberg  DA .  An open study of B lymphocyte depletion in systemic 
lupus erythematosus .  Arthritis Rheum.  2002 ; 46 : 2673 – 7 . 
 Lu  TY ,  Ng  KP ,  Cambridge  G ,  Leandro  MJ ,  Edwards  JC , 6. 
Ehrenstein  M ,  Isenberg DA .  A retrospective seven-year analysis of the 
use of B cell depletion therapy in systemic lupus erythematosus at 
University College London Hospital: the ﬁ rst ﬁ fty patients .  Arthritis 
Rheum.  2009 ; 61(4) : 482 – 7 . 
 Jonsdottir  T ,  Gunnarsson  I ,  Mourao  AF ,  Lu  TY ,  van Vollenhoven  RF , 7. 
 Isenberg  D .  Clinical improvements in proliferative vs membranous 
lupus nephritis following B-cell depletion: pooled data from two 
cohorts .  Rheumatology (Oxford).  2010 ; 49(8) : 1502 – 4 . 
 Melander  C ,  Sallee  M ,  Trolliet  P ,  Candon  S ,  Belenfant  X , 8. 
Daugas  E ,  et  al .  Rituximab in severe lupus nephritis: early B-cell 
depletion aﬀ ects long-erm renal outcome .  Clin J Am Soc Nephrol. 
 2009 ; 4(3) : 579 – 87 . 
 Merrill  JT ,  Neuwelt  CM ,  Wallace  DJ ,  Shanahan  JC ,  Latinis  KM , 9. 
Oates  JC ,  et  al .  Eﬃ  cacy and safety of rituximab in moderately-
to-severely active systemic lupus erythematosus: the randomized, 
double-blind, phase II/III systemic lupus erythematosus evaluation of 
rituximab trial .  Arthritis Rheum.  2010 ; 62(1) : 222 – 33 . 
 Rovin  BH ,  Furie  R ,  Latinis  K ,  Looney  RJ ,  Fervenza  FC ,  Sanchez-10. 
Guerrero  J ,  et  al .  Eﬃ  cacy and safety of rituximab in patients with 
active proliferative lupus nephritis: the lupus nephritis assessment 
with rituximab study .  Arthritis Rheum.  2012 ; 64(4) : 1215 – 26 . 
 Tew  GW ,  Rabbee  N ,  Wolslegel  K ,  Hsieh  H-J ,  Monroe  JG ,  et  al . 11. 
 Baseline autoantibody proﬁ les predict normalization of complement 
and anti-dsDNA autoantibody levels following rituximab treatment in 
systemic lupus erythematosus .  Lupus.  2010 ; 19(2) : 146 – 57 . 
 Hahn  BH ,  McMahon  MA ,  Wilkinson  A ,  Wallace  WD ,  Daikh  DI , 12. 
 Fitzgerald  JD ,  et  al .  American College of Rheumatology guidelines 
for screening, treatment, and management of lupus nephritis .  Arthritis 
Care Res.  2012 ; 64(6) : 797 – 808 . 
 Bertsias  GK ,  Tektonidou  M ,  Amoura  Z ,  Aringer  M ,  Bajema  I , 13. 
Berden  JHM ,  et  al .  Joint European League Against Rheumatism 
and European Renal Association-European Dialysis and Transplant 
Association (EULAR/ERA-EDTA) recommendations for the 
management of adult and paediatric lupus nephritis .  Ann Rheum Dis. 
 2012 ; 71(11) : 1771 – 82 . 
 Hochberg  MC .  Updating the American College of Rheumatology 14. 
revised criteria for the classiﬁ cation of systemic lupus erythematosus . 
 Arthritis Rheum  1997 ; 40(9) : 1725 . 
 Hay  EM ,  Bacon  PA ,  Gordon  C ,  Isenberg  DA ,  Maddison  P ,  Snaith  ML , 15. 
 et  al .  The BILAG index: a reliable and valid instrument for measuring 
clinical disease activity in systemic lupus erythematosus .  Q J Med. 
 1993 ; 86(7) : 447 – 58 . 
 Renal Disease Subcommittee of the American College of 16. 
Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus 
Response Criteria .  The American College of Rheumatology response 
criteria for proliferative and membranous renal disease in systemic 
lupus erythematosus clinical trials .  Arthritis Rheum.  2006 ; 54(2) : 
421 – 32 . 
 Markowitz  GS ,  D ’ Agati  VD .  The ISN/RPS 2003 classiﬁ cation of lupus 17. 
nephritis: an assessment at 3 years .  Kidney Int.  2007 ; 71(6) : 491 – 5 . 
DOI 10.3109/14397595.2015.1060665   Eﬃ  cacy and safety of rituximab in Japanese SLE patients 85
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 T
su
ku
ba
] a
t 1
9:1
0 1
4 J
un
e 2
01
6 
 Ezeonyeji  A ,  Isenberg  D .  Early treatment with rituximab in newly 27. 
diagnosed systemic lupus erythematosus patients: a steroid-sparing 
regimen .  Rheumatology  2012 ; 51(3) : 476 – 81 . 
 Stone  J ,  Merkel  P ,  Spiera  R ,  Seo  P ,  Langford  C ,  Hoﬀ man  G ,  et  al . 28. 
 Rituximab versus Cyclophosphamide for ANCA-associated vasculitis . 
 N Eng J Med.  2010 ; 363(3) : 221 – 32 . 
 Joly  P ,  Mouquet  H ,  Roujeau  JC ,  D ’ lncan  M ,  Gilbert  D ,  Jacquot  S , 29. 
 et  al .  A single cycle of rituximab for treatment of severe pemphigus .  N 
Eng J Med.  2007 ; 357(6) : 545 – 52 . 
 Iijima  K ,  Sako  M ,  Nozu  K ,  Mori  R ,  Tuchida  N ,  Kamei ,  K ,  et  al . 30. 
 Rituximab for childhood-onset, complicated, frequently relapsing 
nephrotic syndrome or steroid-dependent nephrotic syndrome: a 
multicentre, double-blind, randomized, placebo-controlled trial . 
 Lancet  2014 ; 384(9950) : 1273 – 81 . 
 Takei  T ,  Itabashi  M ,  Moriyama  T ,  Kojima  C ,  Shiohira  S ,  Shimizu  A , 31. 
 et  al .  Eﬀ ect of single-dose rituximab on steroid-dependent minimal-
change nephrotic syndrome in adults .  Nephrol Dial Transplant. 
 2013 ; 28(5) : 1225 – 32 . 
 Condon  M ,  Ashby  D ,  Pepper  R ,  Cook  H ,  Levy  J ,  Griﬃ  th  M ,  et  al . 32. 
 Prospective observational single-centre cohort study to evaluate 
the eﬀ ectiveness of treating lupus nephritis with rituximab and 
mycophenolate mofetil but no oral steroids .  Ann Rheum Dis. 
 2013 ; 72(8) : 1280 – 6 . 
 Imperial College London .  Trial of Rituximab and Mycophenolate 33. 
Mofetil Without Oral Steroid for Lupus Nephritis (RITUXILUP). 
NCT01773616 .  Available from: www.ClinicalTrials.gov. 
 Houssiau  FA ,  on behalf of European Working Party on Systemic Lupus 34. 
Erythematosus Lupus Nephritis Trial Network .  RING: rituximab for 
lupus nephritis with remission as a goal. NCT01673295 .  Available 
from: www.ClinicalTrials.gov. 
 Terrier  B ,  Amoura  Z ,  Ravaud  P ,  Hachulla  E ,  Jouenne  R ,  Combe  B , 18. 
 et  al .  Safety and eﬃ  cacy of rituximab in systemic lupus erythematosus: 
results from 136 patients from the French AutoImmunity and 
Rituximab registry .  Arthritis Rheum.  2010 ; 62(8) : 2458 – 66 . 
 D í az-Lagares  C ,  Croca  S ,  Sangle  S ,  Vital  EM ,  Catapano  F , 19. 
Mart í nez-Berriotxoa  A ,  et  al .;  UK-BIOGEAS Registry .  Eﬃ  cacy of 
rituximab in 164 patients with biopsy-proven lupus nephritis: pooled 
data from European cohorts .  Autoimmun Rev.  2012 ; 11(5) : 357 – 64 . 
 Weidenbusch  M ,  Rommele  C ,  Schrottle  A ,  Anders  HJ .  Beyond the 20. 
LUNAR trial. Eﬃ  cacy of rituximab in refractory lupus nephritis . 
 Nephrol Dial Transplant.  2013 ; 28(1) : 106 – 11 . 
 Murray  E ,  Perry  M .  Oﬀ -label use of rituximab in systemic 21. 
lupus erythematosus: a systematic review .  Clin Rheumatol. 
 2010 ; 29(7) : 707 – 16 . 
 Ramos-Casals  M ,  Soto  MJ ,  Cuadrado  MJ ,  Khamashta  MA .  Rituximab 22. 
in systemic lupus erythematosus: A systematic review of oﬀ -label use 
in 188 cases .  Lupus.  2009 ; 18(9) : 767 – 76 . 
 Ready  V ,  Jayne  D ,  Close  D ,  Isenberg  D .  B-cell depletion in SLE: 23. 
clinical and trial experience with rituximab and ocrelizumab and 
implications for study design .  Arthritis Res Ther.  2013 ; 15(Suppl 
1) : S2 . 
 Murphy  G ,  Lisnevskaia  L ,  Isenberg  D .  Systemic lupus erythematosus 24. 
and other autoimmune rheumatic diseases: challenges to treatment . 
 Lancet.  2013 ; 382 : 809 – 18 . 
 Lisnevskaia  L ,  Murphy  G ,  Isenberg  D .  Systemic lupus erythematosus . 25. 
 Lancet.  2014 ; 384 : 1878 – 88 . 
 Pepper  R ,  Griﬃ  th  M ,  Kirwan  C ,  Levy  J ,  Taube  D ,  Pusey  C ,  et  al . 26. 
 Rituximab is an eﬀ ective treatment for lupus nephritis and allows 
a reduction in maintenance steroids .  Nephrol Dial Transplant. 
 2009 ; 24(12) : 3717 – 23 . 
Y. Tanaka et al. Mod Rheumatol, 2016; 26(1):80–8686 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 T
su
ku
ba
] a
t 1
9:1
0 1
4 J
un
e 2
01
6 
